Home > Healthcare > Pharmaceuticals > Drug Delivery > Nasal Drug Delivery Technology Market

Nasal Drug Delivery Technology Market Share

Report ID: GMI12155
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Nasal Drug Delivery Technology Market Share

The nasal drug delivery technology industry is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A key aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Nasal Drug Delivery Technology Market Companies

Some of the eminent market participants operating in the nasal drug delivery technology industry include:

Aegis Therapeutics
AptarGroup
Boehringer Ingelheim
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline
Horizon Therapeutics
Johnson & Johnson
Merck
Nasal Technologies
Neuralstem
Pfizer
Regeneron Pharmaceuticals
Takeda Pharmaceutical Company
XenoPort

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of nasal drug delivery technology reached USD 71.9 billion in 2023 and is set to grow at a 6.8% CAGR from 2024 to 2032, driven by increased demand for non-invasive drug delivery systems.

The non-pressurized containers segment held an 82.2% market share in 2023, as they offer improved ease of use for patients, particularly in self-administration scenarios.

The U.S. market was valued at USD 30 billion in 2023 and is expected to expand at a CAGR of 6.9% over the forecast period, propelled by the high prevalence of allergic conditions and asthma.

Key players in the industry include Aegis Therapeutics, AptarGroup, Boehringer Ingelheim, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline, Horizon Therapeutics, Johnson & Johnson, Merck, Nasal Technologies.